Treatment with the selective TAAR1 antagonist EPPTB substantially improved colitis symptoms, including reduced weight loss, lower DAI scores, prevention of colon shortening, diminished tissue damage, and decreased expression of pro-inflammatory cytokines (TNF-α, IL-6, and IL-1β) in colonic tissue. The gene discussed is IL6; the disease is colitis.